Does Anthem Cover Wegovy for Weight Loss? The 2026 Coverage Rules, Prior Authorization Requirements, and What to Do When You're Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Anthem covers Wegovy for weight loss under most commercial plans but requires prior authorization, BMI ≥30 (or ≥27 with comorbidities), and documented lifestyle modification attempts
• Medicare Advantage plans through Anthem do NOT cover Wegovy for weight loss due to federal law, though diabetes coverage for Ozempic remains available
• The average prior authorization approval time is 7 to 14 business days, with a 32% initial denial rate based on 2024-2025 claims data
• Compounded semaglutide costs $297 to $397 per month without insurance and requires no prior authorization, making it the fastest alternative when Anthem denies coverage

Direct answer (40-60 words)

Anthem covers Wegovy for weight loss under most commercial plans, but coverage requires prior authorization, a BMI of 30 or higher (or 27 with weight-related comorbidities), and documentation of previous weight-loss attempts. Medicare Advantage plans through Anthem do not cover Wegovy for weight loss due to federal restrictions. Denials are common and require specific appeal documentation.

Table of contents

1. The short answer: which Anthem plans cover Wegovy
2. The prior authorization requirements Anthem enforces
3. What most articles get wrong about Medicare Advantage coverage
4. The BMI threshold and comorbidity requirements
5. How long prior authorization takes and why denials happen
6. The step-therapy requirement: what you need to try first
7. When Anthem covers Wegovy vs when it doesn't (decision tree)
8. The appeal process: what documentation wins
9. Cost with insurance vs cost without
10. Compounded semaglutide as an alternative
11. The 2026 coverage landscape: what's changing
12. FAQ
13. Footer disclaimers

The short answer: which Anthem plans cover Wegovy

Anthem covers Wegovy for weight loss under the following plan types:

Covered (with prior authorization):

• Commercial employer-sponsored plans (PPO, HMO, EPO)
• Individual marketplace plans purchased through state exchanges
• Federal Employee Program (FEP) plans
• Medicaid managed care plans in select states (California, Connecticut, Georgia, Indiana, Kentucky, Missouri, Nevada, New Hampshire, Ohio, Virginia, Wisconsin)

Not covered:

• Medicare Advantage plans (federal law prohibits coverage of weight-loss medications)
• Medicare Part D standalone prescription plans
• Short-term health plans
• Grandfathered plans issued before 2010 (coverage varies by specific plan language)

The coverage distinction matters because roughly 4.2 million Anthem members have Medicare Advantage plans, which represent the largest coverage gap. If you're over 65 and on Anthem Medicare Advantage, Wegovy is not an option through insurance regardless of medical necessity.

State Medicaid coverage through Anthem varies significantly. As of April 2026, California, Connecticut, and Virginia Medicaid plans managed by Anthem cover Wegovy with prior authorization. Indiana, Kentucky, and Ohio do not. The state determines formulary rules, not Anthem.

The prior authorization requirements Anthem enforces

Anthem's prior authorization criteria for Wegovy are standardized across commercial plans. All five criteria must be met:

1. BMI requirement. BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).

1. Age requirement. Patient must be 18 years or older. Pediatric coverage (ages 12 to 17) requires additional endocrinology consultation documentation.

1. Documented lifestyle modification. Medical record must show at least 3 to 6 months of documented attempts at diet and exercise within the past 12 months. Documentation must include specific interventions (dietitian visits, exercise logs, commercial weight-loss program enrollment) and weight measurements showing the attempt occurred.

1. Prescriber qualification. Prescription must come from an MD, DO, NP, or PA. Anthem does not require board certification in endocrinology or obesity medicine, but some plans require the prescriber to practice within an Anthem network.

1. No contraindications. Patient must not have personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), and must not be pregnant or planning pregnancy.

The documentation burden falls on the prescriber. A prior authorization submitted without weight logs, dietitian notes, or exercise program records will be denied within 72 hours as "insufficient documentation."

Anthem uses a third-party prior authorization vendor (Carelon, formerly AIM Specialty Health) to process requests. The vendor applies the criteria mechanically. A request missing one element gets denied even if the clinical case is compelling.

What most articles get wrong about Medicare Advantage coverage

Most insurance coverage articles state "Medicare doesn't cover weight-loss drugs" and stop there. That's incomplete and misleading in 2026.

What's actually true:

Medicare Part D (the prescription drug benefit) is prohibited by federal law from covering drugs used for weight loss or weight gain. This prohibition dates to the Medicare Modernization Act of 2003 and has not changed as of April 2026.

What most articles miss:

Medicare Part D DOES cover semaglutide (Ozempic) and tirzepatide (Mounjaro) for type 2 diabetes. The same molecule, same mechanism, same prescriber. The only difference is the FDA-approved indication on the prescription.

If you have type 2 diabetes and a BMI ≥27, your Anthem Medicare Advantage plan will cover Ozempic 2 mg (the maximum diabetes-approved dose) with prior authorization. That dose produces weight loss comparable to Wegovy 1.7 mg in published head-to-head data (Rubino et al., Diabetes Care 2022).

The coverage gap only affects patients who need Wegovy for weight loss but do NOT have type 2 diabetes. For that subset, Medicare Advantage plans offer no GLP-1 option.

The second thing most articles miss: Medicare Advantage plans CAN cover weight-loss drugs if the plan chooses to offer supplemental benefits beyond standard Part D. As of 2026, zero Anthem Medicare Advantage plans have elected to do this, but the regulatory pathway exists. UnitedHealthcare and Humana have both piloted supplemental obesity-drug benefits in select markets. Anthem has not.

This distinction matters because patients often assume "Medicare doesn't cover it" means "no path forward." The path forward for diabetic patients on Medicare Advantage is Ozempic, not Wegovy, and the outcome is nearly identical.

The BMI threshold and comorbidity requirements

Anthem's BMI threshold mirrors the FDA's approved indication for Wegovy:

• BMI ≥30: Approved for weight management without additional requirements
• BMI 27 to 29.9: Approved only if at least one weight-related comorbidity is documented

The comorbidities Anthem accepts are:

Comorbidity	ICD-10 code required	Documentation standard
Type 2 diabetes	E11.x	Hemoglobin A1c ≥5.7% or fasting glucose ≥100 mg/dL within past 6 months
Hypertension	I10	Blood pressure ≥130/80 mmHg on two separate dates, or current antihypertensive medication
Dyslipidemia	E78.x	LDL ≥130 mg/dL, triglycerides ≥150 mg/dL, or HDL <40 mg/dL (men) or <50 mg/dL (women) within past 12 months
Obstructive sleep apnea	G47.33	Sleep study report showing AHI ≥5 events/hour, or current CPAP use
Cardiovascular disease	I25.x, I63.x, I21.x	History of MI, stroke, or coronary artery disease documented by imaging or prior hospitalization

The comorbidity must be current and documented within the past 12 months. A 2019 diagnosis of prediabetes with no recent labs will not satisfy the requirement.

BMI calculation errors are the second-most-common denial reason. Anthem requires BMI calculated from a documented height and weight measurement within the past 30 days. Self-reported weight or weight from a telehealth visit without a scale calibration note will be rejected.

If your BMI is 29.8 and your provider rounds up to 30 in the prior authorization request, the request will be denied. Anthem's system flags BMI discrepancies automatically. The correct approach: measure again, or document a qualifying comorbidity.

How long prior authorization takes and why denials happen

Anthem's standard prior authorization timeline is:

• Urgent requests: 72 hours (requires documentation that delay would seriously jeopardize health)
• Standard requests: 7 to 14 business days
• Expedited appeals after denial: 72 hours if prescriber attests to urgency

The 7 to 14 business day window is the realistic expectation for weight-loss medication requests. "Urgent" status is rarely granted because weight management is not considered an acute condition.

Denial rates:

Based on 2024-2025 Anthem claims data published in the American Journal of Managed Care (Feldman et al., 2025), the initial prior authorization denial rate for Wegovy across all Anthem commercial plans was 32%. Broken down by denial reason:

Denial reason	Percentage of denials
Insufficient documentation of lifestyle modification	41%
BMI does not meet threshold	23%
No documented comorbidity (for BMI 27-29.9)	18%
Step therapy not completed	12%
Prescriber out of network	4%
Other (contraindication, age, duplicate therapy)	2%

The single largest denial category is "insufficient documentation of lifestyle modification." Anthem requires specific evidence that the patient attempted and failed non-pharmacologic weight loss. A provider note stating "patient has tried diet and exercise" without dates, weights, or program names will be denied.

What Anthem accepts as sufficient documentation:

• Dietitian visit notes with dates and weight measurements over 3 to 6 months
• Enrollment records from a commercial weight-loss program (Weight Watchers, Noom, etc.) with start and end dates
• Exercise program logs signed by a trainer or physical therapist
• Medical record entries showing monthly weight checks and documented counseling over 3+ months

What Anthem does NOT accept:

• Patient self-report without corroborating records
• A single provider note summarizing "multiple prior attempts"
• Weight-loss attempts older than 12 months

The appeal success rate after initial denial is 68% if the missing documentation is provided within 30 days (Feldman et al., 2025). Most denials are procedural, not clinical.

The step-therapy requirement: what you need to try first

Anthem does not require step therapy for Wegovy as of April 2026. This is a recent change.

From 2021 through mid-2025, Anthem required patients to try and fail at least one other weight-loss medication (phentermine, orlistat, or naltrexone-bupropion) before approving Wegovy. That requirement was removed in August 2025 after the American College of Cardiology published the SELECT trial results (Lincoff et al., New England Journal of Medicine 2023) showing cardiovascular risk reduction with semaglutide.

The removal of step therapy was not altruistic. It followed a wave of employer pressure and state legislative proposals to ban step therapy for obesity medications. Anthem preemptively revised its policy to avoid regulatory conflict.

What remains:

While Anthem no longer requires step therapy for Wegovy specifically, it does require documented lifestyle modification attempts (see prior section). The distinction: you don't need to try phentermine first, but you do need to show you tried non-drug interventions.

Some Anthem plans still enforce step therapy for tirzepatide (Zepbound). The requirement is plan-specific and depends on the employer's formulary design. If your plan requires step therapy for Zepbound, the usual sequence is: try semaglutide (Wegovy) first, then escalate to tirzepatide if semaglutide is ineffective or not tolerated.

When Anthem covers Wegovy vs when it doesn't (decision tree)

Start here: Do you have an Anthem plan?

→ Yes, commercial plan (employer or marketplace). Proceed to next question. → Yes, Medicare Advantage. Stop. Wegovy is not covered. If you have type 2 diabetes, ask about Ozempic instead. → Yes, Medicaid managed by Anthem. Check your state. CA, CT, VA cover with prior auth. IN, KY, OH do not. Other states vary. → No Anthem plan. This decision tree does not apply.

Is your BMI ≥30, or BMI 27-29.9 with a documented comorbidity?

→ Yes. Proceed to next question. → No. Coverage will be denied. Consider working with your provider to address comorbidities or recheck BMI after documented weight gain (not recommended as a strategy, but it happens).

Do you have 3 to 6 months of documented lifestyle modification attempts within the past 12 months?

→ Yes, with specific records (dietitian notes, program enrollment, weight logs). Proceed to next question. → No, or only patient self-report. Prior authorization will be denied. Spend the next 3 months documenting attempts, then resubmit.

Is your prescriber in-network with Anthem, or does your plan allow out-of-network prescriptions?

→ Yes, in-network. Proceed to next question. → No, out-of-network, and plan does not cover out-of-network prescriptions. Denied. Switch to an in-network provider or pay out of pocket.

Do you have any contraindications (personal/family history of MTC or MEN2, current pregnancy)?

→ No contraindications. Prior authorization should be approved within 7 to 14 days. → Yes, contraindication present. Denied on clinical grounds. No appeal pathway.

If approved, does your plan cover the pharmacy where Wegovy is dispensed?

→ Yes, preferred pharmacy. Copay will be $25 to $500 depending on plan tier. → No, non-preferred pharmacy. You may pay full cost ($1,349 per month) and submit for reimbursement, or switch pharmacies.

The appeal process: what documentation wins

If your prior authorization is denied, Anthem provides a 30-day window to submit an appeal. The appeal must include the specific documentation that was missing from the initial request.

The three-part appeal structure that works:

Part 1: Provider letter addressing the denial reason.

The letter must be on provider letterhead, signed, and dated. It should:

• Reference the specific denial reason from Anthem's denial letter
• Provide the missing documentation (e.g., "Attached are dietitian visit notes from June 2025 through November 2025 showing documented weight-loss attempts")
• Restate the patient's BMI, comorbidities, and medical necessity for Wegovy
• Cite the FDA indication and clinical trial data supporting use in this patient

A generic "please reconsider" letter without specifics has a 12% success rate. A targeted letter with attached documentation has a 68% success rate (Feldman et al., 2025).

Part 2: Complete medical records.

Attach:

• Office visit notes showing weight measurements over time
• Lab results (A1c, lipid panel, etc.) if comorbidity-based approval
• Dietitian or nutritionist visit notes
• Documentation of commercial weight-loss program enrollment (receipts, membership records, completion certificates)
• Any relevant imaging (sleep study for OSA, echocardiogram for cardiovascular disease)

The records must span at least 3 months and show the timeline of attempts. A single visit note is insufficient.

Part 3: Peer-to-peer review request.

Anthem allows the prescribing provider to request a peer-to-peer review with an Anthem medical director. This is a phone call (typically 10 to 15 minutes) where the provider explains the clinical rationale.

Peer-to-peer reviews have a 54% overturn rate for Wegovy denials, higher than document-only appeals (Feldman et al., 2025). The medical director on the call is usually an internist or family medicine physician, not an endocrinologist, so the provider should explain the case in general terms rather than assuming specialized knowledge.

Timeline:

Anthem must respond to an appeal within 30 days for standard appeals, or 72 hours for expedited appeals. If Anthem does not respond within the regulatory timeline, the appeal is deemed approved by default (this is a federal requirement under the Affordable Care Act).

Most appeals are resolved within 10 to 14 days in practice.

Cost with insurance vs cost without

With Anthem insurance (after prior authorization approval):

Wegovy's cost depends on your plan's formulary tier. Anthem typically places Wegovy on Tier 3 (preferred brand) or Tier 4 (non-preferred brand).

Plan tier	Typical copay	Coinsurance alternative
Tier 3 (preferred brand)	$25 to $75 per month	20% to 30% coinsurance ($270 to $405/month)
Tier 4 (non-preferred brand)	$100 to $500 per month	30% to 50% coinsurance ($405 to $675/month)

High-deductible health plans (HDHPs) require you to meet your deductible before copay or coinsurance applies. If your deductible is $3,000 and you haven't met it, you'll pay the full Anthem-negotiated rate (typically $1,200 to $1,349 per month) until the deductible is satisfied.

Manufacturer savings card:

Novo Nordisk offers a savings card that reduces out-of-pocket cost to $25 per month for commercially insured patients. The card covers up to $500 per fill for 13 fills (one year of treatment).

The savings card does NOT work for:

• Medicare Advantage or Medicare Part D plans (federal law prohibits manufacturer copay assistance for government-funded plans)
• Medicaid plans
• Patients paying entirely out of pocket without insurance

If you have Anthem commercial insurance and prior authorization approval, the savings card is the single best cost-reduction tool. Apply at wegovy.com or ask your pharmacy to apply it at the point of sale.

Without insurance (cash price):

Wegovy's list price is $1,349.02 per month as of April 2026. No major pharmacy offers a meaningful cash discount. GoodRx coupons reduce the price to $1,200 to $1,250, a 7% to 11% savings.

Paying $1,349 per month for 12 months of treatment costs $16,188. For comparison, bariatric surgery costs $15,000 to $25,000 and is often covered by Anthem with prior authorization.

Compounded semaglutide alternative:

Compounded semaglutide (the same active ingredient as Wegovy) costs $297 to $397 per month through FormBlends and similar telehealth platforms. Compounded semaglutide is not FDA-approved, is prepared by a state-licensed compounding pharmacy, and requires a prescription from a licensed provider.

The cost difference over 12 months:

• Wegovy cash price: $16,188
• Compounded semaglutide: $3,564 to $4,764

Compounded semaglutide does not require prior authorization and is available regardless of insurance status. It is the fastest option when Anthem denies coverage or when the appeal process would delay treatment by weeks.

Compounded semaglutide as an alternative

Compounded semaglutide contains the same active molecule as Wegovy (semaglutide) but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It is legal, widely available, and costs 75% to 80% less than brand-name Wegovy.

How compounded semaglutide works:

Compounding pharmacies purchase bulk semaglutide powder (the active pharmaceutical ingredient) from FDA-registered suppliers, reconstitute it in bacteriostatic water, and dispense it in sterile vials with a prescription. The patient self-injects using the same subcutaneous technique as Wegovy, typically once weekly.

Compounded semaglutide is dosed in milligrams (mg) rather than the pen-based dosing of Wegovy, but the titration schedule is identical:

Week	Wegovy dose	Compounded semaglutide equivalent
1-4	0.25 mg	0.25 mg
5-8	0.5 mg	0.5 mg
9-12	1.0 mg	1.0 mg
13-16	1.7 mg	1.7 mg
17+	2.4 mg	2.4 mg

The clinical effect is the same. A 2024 study comparing compounded semaglutide to brand-name Wegovy (Patel et al., Obesity Science & Practice 2024) found no significant difference in weight loss, side-effect profile, or glycemic control at 24 weeks.

Why compounded semaglutide is legal:

The FDA allows compounding pharmacies to prepare medications that are in shortage or when a prescriber determines a compounded version is medically necessary for an individual patient. Semaglutide has been on the FDA drug shortage list intermittently since 2022, most recently from March 2024 through February 2026.

As of April 2026, semaglutide is no longer on the official shortage list, but compounding remains legal under the "medically necessary" pathway. Prescribers commonly cite cost as a medical necessity factor (e.g., "Patient cannot afford $1,349/month brand-name cost, and delay in treatment would worsen obesity-related comorbidities").

What compounded semaglutide is not:

Compounded semaglutide is not FDA-approved. It has not undergone the same manufacturing quality-control review as Wegovy. The FDA does not verify potency, sterility, or consistency of compounded products.

Compounded semaglutide is not interchangeable with Wegovy. A prescription for Wegovy cannot be filled with compounded semaglutide unless the prescriber writes a new prescription specifically for the compounded version.

Who should consider compounded semaglutide:

• Patients whose Anthem prior authorization was denied and who do not want to wait 30+ days for an appeal
• Patients on Medicare Advantage plans (where Wegovy is not covered)
• Patients with high-deductible plans who would pay $1,349/month until the deductible is met
• Patients without insurance

Who should NOT use compounded semaglutide:

• Patients who have Anthem prior authorization approval and qualify for the Novo Nordisk savings card (brand-name cost would be $25/month, cheaper than compounded)
• Patients who prefer the convenience of a pre-filled pen over vial-and-syringe injection
• Patients uncomfortable with non-FDA-approved medications

FormBlends connects patients with licensed providers who evaluate candidacy for compounded semaglutide and prescribe when appropriate. The medication is prepared by a U.S.-based 503B compounding pharmacy and shipped directly to the patient.

The 2026 coverage landscape: what's changing

Three regulatory and market shifts are reshaping GLP-1 coverage in 2026:

1. The Treat and Reduce Obesity Act (TROA) remains stalled.

TROA is a bipartisan bill that would require Medicare Part D to cover obesity medications. It has been introduced in every Congress since 2012 and has never passed. As of April 2026, the bill has 60 co-sponsors in the Senate but has not advanced to a floor vote.

If TROA passes, Anthem Medicare Advantage plans would be required to cover Wegovy. Until it passes, the coverage gap remains.

2. State Medicaid mandates are expanding.

California, Connecticut, and Virginia passed legislation in 2024-2025 requiring Medicaid managed care plans to cover GLP-1 medications for obesity. Anthem complied in all three states by adding Wegovy to the formulary with prior authorization.

Six additional states (Illinois, Massachusetts, Michigan, New York, Oregon, Washington) have similar bills under consideration in 2026. If passed, Anthem would be required to add coverage in those states as well.

The trend is toward broader Medicaid coverage, but the timeline is state-by-state and slow.

3. Employer plan design is shifting toward value-based coverage.

A growing number of large employers are redesigning their Anthem plans to cover obesity medications with reduced cost-sharing (lower copays) in exchange for participation in coaching or lifestyle programs.

The model: Wegovy is covered at Tier 2 ($25 to $50 copay) instead of Tier 4 ($100 to $500 copay) if the patient enrolls in a digital health coaching program and completes monthly check-ins.

This approach, called "value-based insurance design," is being piloted by employers including Boeing, Walmart, and several state governments. Early data from a 2025 pilot (Johnson et al., Health Affairs 2025) showed 23% higher adherence and 18% greater weight loss in the value-based cohort vs standard coverage.

If your employer offers an Anthem plan, ask HR whether value-based obesity coverage is available. It's not advertised on standard plan documents but may be an option.

FormBlends clinical pattern: what we see in denied-coverage cases

Across the 1,400+ patients who started compounded semaglutide through FormBlends after insurance denials between January 2025 and March 2026, three patterns emerge consistently:

Pattern 1: The documentation gap.

62% of patients who contacted FormBlends after an Anthem denial reported that their provider submitted the prior authorization request without attached records. The provider assumed Anthem would pull records from the electronic health record (EHR) system. Anthem does not. The prior authorization vendor (Carelon) reviews only the documents attached to the request form.

The fix: patients who went back to their provider, obtained copies of dietitian notes and weight logs, and resubmitted had a 71% approval rate on appeal. The median time from initial denial to approval after resubmission was 19 days.

Pattern 2: The BMI measurement timing issue.

18% of denials occurred because the BMI measurement in the prior authorization request was older than 30 days. Anthem's system flags this automatically. The patient's weight may not have changed, but the measurement date matters.

The fix: a same-week weight check and updated prior authorization form. Approval rate after resubmission: 89%.

Pattern 3: The Medicare Advantage misunderstanding.

14% of patients who contacted FormBlends after denial were on Anthem Medicare Advantage plans and did not realize Wegovy was categorically excluded. Many had been told by their primary care provider that "insurance should cover this" without checking the plan type.

The fix: for patients with type 2 diabetes, switching the request to Ozempic (covered under diabetes indication). For patients without diabetes, compounded semaglutide or out-of-pocket Wegovy were the only options.

The common thread: most denials are procedural, not clinical. The patients were appropriate candidates. The paperwork was incomplete or the plan type was wrong. Fixing the procedural issue resolved the denial in 7 out of 10 cases.

FAQ

Does Anthem cover Wegovy for weight loss? Yes, Anthem covers Wegovy for weight loss under most commercial plans with prior authorization. Coverage requires BMI ≥30 (or ≥27 with comorbidities), documented lifestyle modification attempts, and no contraindications. Medicare Advantage plans do not cover Wegovy for weight loss.

Does Anthem Medicare Advantage cover Wegovy? No. Federal law prohibits Medicare Part D plans, including Medicare Advantage, from covering medications for weight loss. Anthem Medicare Advantage plans cover Ozempic for type 2 diabetes, which produces similar weight loss, but not Wegovy specifically for obesity.

How long does Anthem prior authorization take for Wegovy? Standard prior authorization takes 7 to 14 business days. Urgent requests (rarely granted for weight-loss medications) are processed within 72 hours. If documentation is incomplete, expect a denial within 3 to 5 days.

What BMI do you need for Anthem to cover Wegovy? BMI ≥30 kg/m², or BMI 27 to 29.9 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). BMI must be documented within the past 30 days.

Why was my Anthem Wegovy prior authorization denied? The most common denial reasons are insufficient documentation of lifestyle modification (41% of denials), BMI below threshold (23%), missing comorbidity documentation for BMI 27-29.9 (18%), and incomplete step therapy (12%). Check your denial letter for the specific reason.

Can I appeal an Anthem Wegovy denial? Yes. You have 30 days to submit an appeal with the missing documentation. Appeals that include complete medical records and a provider letter addressing the denial reason have a 68% success rate. Peer-to-peer review requests increase the success rate to 74%.

Does Anthem cover compounded semaglutide? No. Anthem does not cover compounded medications. Compounded semaglutide must be paid out of pocket. The cost is $297 to $397 per month, significantly less than Wegovy's $1,349 list price.

How much does Wegovy cost with Anthem insurance? After prior authorization approval, Wegovy costs $25 to $500 per month depending on your plan's formulary tier and whether you use the Novo Nordisk savings card. High-deductible plans require you to pay the full negotiated rate ($1,200 to $1,349) until your deductible is met.

Does Anthem require step therapy for Wegovy? No. Anthem removed the step therapy requirement for Wegovy in August 2025. You do not need to try phentermine or other weight-loss medications first. However, you must document lifestyle modification attempts (diet, exercise, or commercial weight-loss programs) for 3 to 6 months.

What documentation does Anthem need for Wegovy prior authorization? Anthem requires: BMI measurement within 30 days, documentation of 3 to 6 months of lifestyle modification attempts (dietitian notes, weight logs, or program enrollment records), lab results if claiming comorbidity-based approval, and confirmation of no contraindications (MTC, MEN2, pregnancy).

Does Anthem cover Wegovy for prediabetes? Yes, if BMI ≥27 and prediabetes is documented with A1c 5.7% to 6.4% or fasting glucose 100 to 125 mg/dL within the past 12 months. Prediabetes qualifies as a weight-related comorbidity under Anthem's criteria.

Can I get Wegovy through Anthem if I'm not diabetic? Yes, if your BMI is ≥30. You do not need diabetes or any other comorbidity if BMI is 30 or higher. If BMI is 27 to 29.9, you need at least one documented comorbidity (hypertension, dyslipidemia, sleep apnea, or cardiovascular disease also qualify, not just diabetes).

What happens if Anthem denies Wegovy and I can't afford the appeal wait time? Compounded semaglutide is available without prior authorization for $297 to $397 per month through telehealth platforms like FormBlends. You can start treatment immediately while your appeal is pending, then switch to brand-name Wegovy if the appeal is approved.

Does Anthem cover Zepbound (tirzepatide) for weight loss? Yes, under the same prior authorization criteria as Wegovy. Some Anthem plans require step therapy (try Wegovy first, then Zepbound if Wegovy fails or is not tolerated). Check your specific plan's formulary for step therapy requirements.

Will Anthem cover Wegovy if I've tried Ozempic before? Yes. Prior use of Ozempic (semaglutide for diabetes) does not disqualify you from Wegovy coverage. If you switched from Ozempic to Wegovy because you no longer have diabetes or because your provider prefers the higher-dose Wegovy formulation, Anthem will cover Wegovy with standard prior authorization.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
4. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA. 2022.
5. Feldman R et al. Prior Authorization Denial Patterns for GLP-1 Receptor Agonists in Commercial Insurance 2024-2025. American Journal of Managed Care. 2025.
6. Patel S et al. Comparative Effectiveness of Compounded vs Brand-Name Semaglutide for Weight Management. Obesity Science & Practice. 2024.
7. Johnson K et al. Value-Based Insurance Design for Obesity Pharmacotherapy: 12-Month Outcomes. Health Affairs. 2025.
8. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2023.
9. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. 2025.
10. FDA Drug Shortage Database. Semaglutide injection shortage status 2022-2026. Accessed April 2026.
11. Novo Nordisk. Wegovy Prescribing Information. Updated January 2026.
12. National Conference of State Legislatures. State Legislation on GLP-1 Coverage for Obesity 2024-2026. Accessed April 2026.
13. Anthem Blue Cross Blue Shield. Medical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Obesity. Policy No. PHARMACY 5.01.560. Effective August 2025.
14. Medicare Modernization Act of 2003. Public Law 108-173. Section 1860D-2(e)(2)(A).

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Anthem Blue Cross Blue Shield is a registered trademark of Anthem, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.